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Treatment of intact hepatocytes with the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA) poten- 
tiated the ability of glucagon to increase intracellular cyclic AMP concentrations. This effect was dose-de- 
pendent upon TPA, exhibiting an EC,, of 0.39 ng/ml and such activation was observed at both saturating 
and sub-saturating concentrations of glucagon. However, this stimulatory effect of TPA was completely 
abolished by the presence of the cyclic AMP phosphodiesterase inhibitor 1-isobutyl-3-methylxanthine, when 
TPA now inhibited the glucagon-stimulated increase in intracellular cyclic AMP concentrations. It is sug- 
gested that, as well as inhibiting glucagon-stimulated adenylate cyclase activity, TPA also inhibits cyclic 
AMP phosphodiesterase activity in intact hepatocytes. Treatment of either hepatocyte homogenates or puri- 
fied cyclic AMP phosphodiesterase with TPA failed to show any direct inhibitory effect of TPA on activity 
showing that TPA did not exert any direct inhibitory action on phosphodiesterase activity. However, homo- 
genates made from hepatocytes that had been pre-treated with TPA did show a reduced cyclic AMP phos- 
phodiesterase activity. It is suggested that TPA might inhibit cyclic AMP phosphodiesterase activity 
through phosphorylation by C-kinase. 
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1. INTRODUCTION 
Tumour-promoting phorbol esters such as TPA 
(12-0-tetradecanoyl phorbol-13-acetate) have been 
shown to exert a variety of effects upon cells [ 1,2]. 
It is believed that they achieve such effects by 
stimulating the activity of protein kinase C which, 
in turn, modulates the activity of target proteins by 
eliciting their phosphorylation [3,4]. Recently, 
there has been considerable interest in the possibili- 
ty that C-kinase activation can regulate signal 
transmission through the adenylate cyclase 
pathway [5-151. Indeed, phorbol esters have been 
shown to inhibit the functioning of the inhibitory 
guanine nucleotide regulatory protein Gi, by caus- 
ing its phosphorylation [9,10]. This elimination of 
an inhibitory input is believed to account for the 
TPA-mediated potentiation of adenylate cyclase 
activity that has been observed in S49 mouse lym- 
phoma cells [l 11. However, in a number of other 
systems, phorbol esters have been shown to inhibit 
hormone-stimulated adenylate cyclase activity 
[5-8,12,13]. This inhibitory effect appeared to 
result as a consequence of the loss of productive 
coupling between receptors and the stimulatory 
guanine nucleotide regulatory protein, G, 
[5,6,12,13]. In this way phorbol esters can be seen 
to mimic the rapid uncoupling/desensitization of 
hormone-stimulated adenylate cyclase systems 
[6,12,13]. 
We show here that signal transduction by the 
cyclic AMP pathway can be perturbed by another 
route, namely the inhibition of cellular cyclic AMP 
phosphodiesterase activity. 
2. MATERIALS AND METHODS 
,Hepatocytes from male Sprague-Dawley rats 
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(200-300 g) were prepared and incubated as 
described before by us [16]. The Krebs-Henseleit 
incubation medium contained 2.5% bovine serum 
albumin and 1.5 mM CaC12. Intracellular cyclic 
AMP determinations were performed as described 
before [17] by us, as was the assay of adenylate 
cyclase [16,17]. Cyclic AMP phosphodiesterase ac- 
tivity was assessed at a final substrate concentra- 
tion of 100 nM cyclic AMP using a two-step assay 
procedure [ 181 as described in some detail by us 
[ 191. Initial rates were taken from linear time 
courses. Purification of the ‘dense-vesicle’, 
peripheral plasma membrane [20] and cyclic GMP- 
stimulated cyclic AMP phosphodiesterases [21] 
was performed as described previously by us. 
Hepatocyte homogenates were made as described 
before by us [22]. 
TPA, bovine serum albumin and IBMX were 
from Sigma (Poole, England). Cyclic AMP, 
triethanolamine HCl, collagenase and all other 
biochemicals were from Boehringer (UK) Ltd. 
Glucagon was a kind gift from Dr W.W. Bramer, 
Eli Lilly & Co. (IN, USA). All radiochemicals were 
from Amersham International (Amersham, 
England). 
3. RESULTS AND DISCUSSION 
Challenge of intact hepatocytes with glucagon 
(10 nM) has been shown by us and many others 
previously (see e.g. [16]) to cause a transient rise in 
the intracellular concentration of cyclic AMP 
(fig.la). This action is markedly potentiated 
(fig.lb) by the presence of the non-selective cyclic 
AMP phosphodiesterase (PDE) inhibitor 
1-isobutyl-3-methylxanthine (IBMX) which in- 
hibits over 98% of hepatocyte PDE activity [16]. If 
hepatocytes were pre-incubated with TPA 
(10 ng/ml, 15 min), in the presence of IBMX 
(1 mM), then intracellular cyclic AMP accumula- 
tion triggered by the addition of glucagon (10 nM) 
was markedly reduced. This observation is in ac- 
cord with our observations [5,6] that TPA treat- 
ment of intact hepatocytes inhibited the 
glucagon-stimulated adenylate cyclase activity ex- 
pressed by membranes isolated from them. 
However, if such experiments were repeated in the 
absence of the cyclic AMP phosphodiesterase in- 
hibitor IBMX then, in contrast to the above 
results, the presence of TPA actually enhanced the 
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Fig.1. Time course of glucagon-stimulated cyclic AMP 
accumulation in intact hepatocytes. (a) Hepatocytes 
were pre-incubated with the cyclic AMP phospho- 
diesterase inhibitor IBMX (1 mM) for 20 min prior to 
challenge with glucagon (10 nM) (m). In one instance 
( q ), TPA (10 ng/ml) was added 15 min prior to the 
addition of glucagon. Cells were harvested at the 
indicated times for determination of their intracellular 
cyclic AMP content. (b) As in (a) except hat IBMX was 
not added to the cells. Experiments were done in the 
presence ( q ) or absence ( n ) of TPA (1 ng/ml) as 
detailed above. Data are given with SD for n = 3 
experiments using different cell preparations each with 
triplicate samples and triplicate cyclic AMP deter- 
minations. 
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increase in intracellular cyclic AMP concentrations 
elicited by glucagon markedly (fig. 1). These effects 
were seen clearly over the entire dose range for 
which glucagon stimulated the intracellular ac- 
cumulation of cyclic AMP (fig.2). 
Furthermore, the ability of TPA to potentiate 
the glucagon-stimulated increase in cyclic AMP, 
seen in the absence of IBMX, was shown to be 
dose dependent upon TPA (fig.3) with an EC50 of 
0.39 + 0.05 ng/ml TPA. This value is very similar 
to that observed for the action of TPA in in- 
hibiting adenylate cyclase activity in intact 
hepatocytes [5]. 
In the absence of IBMX, then TPA (10 rig/ml 
for 15 min) even increased @ < 0.001) basal cyclic 
AMP concentrations from 2.8 + 0.1 to 4.0 + 
0.2 pmol/mg dry wt cells (errors are SD, n = 3 
separate experiments, Student’s t-test). This con- 
trasted with a decreased @ Q 0.001) basal ac- 
cumulation from 14.4 * 1.0 pmol/mg dry wt cells 
to, with TPA (10 ng/ml) present, 5.1 + 
0.3 pmol/mg dry wt cells over a 20 min period at 
37°C with IBMX (1 mM) present (errors are SD, n 
= 3 separate experiments, Student’s t-test). 
These results imply that the TPA-mediated 
potentiation of glucagon-stimulated cyclic AMP 
accumulation, which was only seen in the absence 
of the PDE inhibitor IBMX, was due to the ability 
of TPA to inhibit hepatocyte PDE activity. In- 
deed, the relative effectiveness of TPA to inhibit 
PDE activity can be gauged from the observation 
(fig. 1) that IBMX caused a 4.5-fold potentiation of 
the elevated cyclic AMP accumulation seen after 
5 min exposure to glucagon whereas, in the 
absence of IBMX, TPA caused an approx. 
1.3-fold potentiation of the stimulatory effect of 
glucagon. If one takes account of the fact that 
TPA exerts an inhibitory effect on glucagon- 
stimulated adenylate cyclase (-30-40% inhibition; 
observed here and see [5,6]) the maximum effect of 
TPA at potentiating the glucagon-stimulated cyclic 
AMP accumulation through PDE inhibition can 
be estimated as being around 2-fold. This approx- 
imates to TPA exerting an inhibitory effect on 
cyclic AMP phosphodiesterase activity which was 
around 25% of the potency of the effect elicited by 
IBMX, which inhibits >98% of hepatocyte PDE 
activity [ 161. 
The addition of a range of concentrations of 
TPA (lo-100 ng/ml) to assays of total hepatocyte 
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Dose-response curve glucagon-stimulated cyclic 
accumulation in hepatocytes. (a) 
were pre-incubated IBMX (1 for 
20 prior to with glucagon the indicated 
After 5 the cells harvested for 
of their cyclic AMP 
(w). In instance ( q ), TPA (10 ng/ml) was added 
15 min prior to challenge with glucagon. (b) As in (a) 
except hat IBMX was absent. Cells either were (0) or 
were not (u) pre-treated with TPA (10 ng/ml) as above. 
Data are given with SD for n = 3 experiments using 
different cell preparations each with triplicate samples 
and triplicate cyclic AMP determinations. 
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Fig.3. In intact hepatocytes TPA produces a dose- 
dependent enhancement of the glucagon-stimulated 
increase in cychc AMP when cyclic AMP 
phosphodiesterase inhibitors are absent. Hepatocytes 
were incubated at 37*C with increasing concentrations 
of the phorbol ester TPA for a 10 min period. After this, 
they were challenged with glucagon (10 r&l) for a 5 min 
period prior to harvesting for analysis of their 
intracellular cyclic AMP content. Data are given with 
SD for n = 3 experiments using different cell 
preparations each with triplicate samples and triplicate 
cyclic AMP determinations. 
homogenate PDE activity or to purified prepara, 
tions of rat liver dense-vesicle PDE, peripheral 
plasma membrane PDE and cyclic GMP- 
stimulated PDE failed to exert any effect on activi- 
ty (less than 5% change). However, we did observe 
inhibition of the PDE activity exhibited by 
hepatocyte homogenates made from intact cells 
which had been pre-treated with TPA. In such 
preparations, hepatocytes were pre-incubated with 
TPA (100 ng/ml) for 15 min prior to homogenisa- 
tion in the presence of 50 mM fl-glycerophosphate, 
which has been shown to inhibit the 
dephosphorylation of proteins phosphorylated by 
the action of C-kinase [23]. These studies showed 
that TPA elicited a 20 & 3% inhibition of total 
homogenate PDE activity (errors are SD, n = 6 
separate experiments). Such a degree of PDE in- 
hibition is similar to that estimated above to ac- 
count for TPA’s ability to potentiate the 
glu~agon-stimulated increase in intracellular cyclic 
AMP accumulation observed in the absence of 
IBMX. 
These experiments demonstrate that, as well as 
modulating adenylate cyclase functioning, TPA 
can also inhibit hepatocyte PDE activity. This 
observation may have important physiological 
consequences as well as demanding a re- 
investigation of the actions of TPA on intracellular 
cyclic AMP accumulation in studies performed in 
the absence of PDE inhibitors (e.g. see [IS]). Our 
investigations also suggest hat ligands which in- 
itiate diacylglycerol production in cells, by 
stimulating inositol phospholipid metabolism, may 
also regulate cyclic AMP phosphodiesterase activi- 
ty through a route similar to that employed by 
TPA. 
Rat hepatocytes contain a family of distinct 
PDE isoenzymes whose relative importance in con- 
trolling intracellular cyclic AMP concentrations is 
only partially understood [24-261. It remains to be 
determined as to which species are regulated by 
TPA and whether phosphorylation by C-kinase is 
involved. 
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